RZLT Stock Summary and Trading Ideas (Rezolute - Common (Nv) | NASDAQ:RZLT)

Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.

Rezolute - Common (Nv) trades on the NASDAQ stock market under the symbol RZLT.

As of October 13, 2026, RZLT stock price declined to $4.61 with 1,461,321 million shares trading.

RZLT has a beta of 1.25, meaning it tends to be more sensitive to market movements. RZLT has a correlation of 0.01 to the broad based SPY ETF.

RZLT has a market cap of $445.89 million. This is considered a Small Cap stock.

In the last 3 years, RZLT traded as high as $11.46 and as low as $.72.

The top ETF exchange traded funds that RZLT belongs to (by Net Assets): VTI, IWM, VXF, IWN, DFAS.

RZLT has underperformed the market in the last year with a return of -44.3%, while the SPY ETF gained +18.5%. In the last 3 month period, RZLT fell short of the market, returning -2.9%, while SPY returned +4.1%. However, in the most recent 2 weeks RZLT has outperformed the stock market by returning +10.3%, while SPY returned +1.8%.

RZLT support price is $4.61 and resistance is $5.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RZLT shares will trade within this expected range on the day.